GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cantargia AB (OSTO:CANTA) » Definitions » Cash Receipts from Fees and Commissions

Cantargia AB (OSTO:CANTA) Cash Receipts from Fees and Commissions


View and export this data going back to 2015. Start your Free Trial

What is Cantargia AB Cash Receipts from Fees and Commissions?

Cash Receipts from Fees and Commissions only applicable to companies reporting Cash Flow from Operations in direct method.


Cantargia AB Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cantargia AB (OSTO:CANTA) » Definitions » Cash Receipts from Fees and Commissions
Traded in Other Exchanges
Address
Scheelevagen 27, Lund, SWE, 223 63
Cantargia AB is a Swedish biotech company that develops targeted antibody-based drugs for cancer as well as autoimmune and inflammatory diseases. It has developed specific antibodies against IL1RAP to treat serious, life-threatening diseases. The company's development programme includes the candidate drugs nadunolimab (CAN04) and CAN10, both in the clinical development stage, as well as its antibody platform CANxx.